U.S. Drug Utilization Management Market Size, Share & Trends Analysis Report by Program Type (In-House, Outsourced), End-use (PBMs, Health Plan Providers/Payors, Pharmacies), and Segment Forecasts, 2024-2030

1.1. Market Segmentation & Scope
1.1.1. Estimates and Forecast Timeline
1.2. Market Definitions
1.2.1. Segment definitions.
1.2.1.1. Program type
1.2.1.2. End-use
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.4.4.1. Details of Primary Research
1.4.5. Research Assumption
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Data Visualization
1.7. Model Details
1.7.1. Volume Price Analysis
1.7.2. Segment-level market estimation: Multivariate analysis
1.7.3. Multivariate analysis
1.7.4. Forecast & CAGR Calculation
1.8. Objectives
1.9. List of Secondary Sources
1.10. List of Abbreviations

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

3.1. Market Lineage Outlook
3.2. Market Trends and Outlook
3.3. Market Dynamics
3.3.1. Market Driver Analysis
3.3.1.1. Increasing demand for automated utilization management systems
3.3.1.2. Need for improving prescription patterns for specialty drugs
3.3.1.3. Growing demand for cost containment in the healthcare industry
3.3.2. Market Restraint Analysis
3.3.2.1. Regulatory and privacy issues
3.3.2.2. Lack of transparency
3.3.3. Industry Opportunity Analysis
3.3.3.1. Growing integration of real-time data analytics in the healthcare industry
3.3.4. Industry Challenges Analysis
3.3.4.1. Delayed access to treatment and hindrance in medication adherence
3.4. Qualitative Analysis: Pricing Analysis on Drug Utilization Management
3.5. Business Environment Analysis Tools
3.5.1. Industry Analysis - Porter’s Five Forces Analysis
3.5.1.1. Supplier power
3.5.1.2. Buyer power
3.5.1.3. Substitution threat
3.5.1.4. Threat of new entrant
3.5.1.5. Competitive rivalry
3.5.2. PESTEL Analysis

4.1. U.S. Drug Utilization Management Market: Program Type Segment Dashboard
4.2. Program Type Movement & Market Share Analysis, 2023 & 2030
4.3. U.S. Drug Utilization Management Market Size & Forecast and Forecasts, By Program Type, 2018-2030 (USD Billion)
4.4. In-House
4.4.1. In-house market, 2018-2030 (USD Billion)
4.5. Outsourced
4.5.1. Outsourced - market, 2018-2030 (USD Billion)

5.1. U.S. Drug Utilization Management Market: End-use Segment Dashboard
5.2. End-use Movement & Market Share Analysis, 2023 & 2030
5.3. U.S. Drug Utilization Management Market Size & Forecast and Forecasts, By End-use (USD Billion)
5.4. PBMs
5.4.1. PBMs market, 2018-2030 (USD Billion)
5.5. Health Plan Provider/Payors
5.5.1. Health Plan Provider/Payors market, 2018-2030 (USD Billion)
5.6. Pharmacies
5.6.1. Pharmacies market, 2018-2030 (USD Billion)

6.1. Participant Categorization
6.2. Company Market Position Analysis
6.3. Strategy Mapping
6.3.1. Expansion
6.3.2. Merger and Acquisition
6.3.3. Partnership/Collaborations/Alliances
6.3.4. Others
6.4. Company Profiles: Third Party Providers
6.4.1. Prime Therapeutics LLC
6.4.1.1. Overview
6.4.1.2. Financial Performance
6.4.1.3. Service Benchmarking
6.4.1.4. Strategic Initiatives
6.4.2. MedicusRx
6.4.2.1. Overview
6.4.2.2. Financial Performance
6.4.2.3. Service Benchmarking
6.4.2.4. Strategic Initiatives
6.4.3. EmblemHealth
6.4.3.1. Overview
6.4.3.2. Financial Performance
6.4.3.3. Service Benchmarking
6.4.3.4. Strategic Initiatives
6.4.4. Optum, Inc.
6.4.4.1. Overview
6.4.4.2. Financial Performance
6.4.4.3. Service Benchmarking
6.4.4.4. Strategic Initiatives
6.4.5. Point32Health, Inc.
6.4.5.1. Overview
6.4.5.2. Financial Performance
6.4.5.3. Service Benchmarking
6.4.5.4. Strategic Initiatives
6.4.6. AssureCare LLC
6.4.6.1. Overview
6.4.6.2. Financial Performance
6.4.6.3. Service Benchmarking
6.4.6.4. Strategic Initiatives
6.4.7. MindRx Group
6.4.7.1. Overview
6.4.7.2. Financial Performance
6.4.7.3. Service Benchmarking
6.4.7.4. Strategic Initiatives
6.4.8. Agadia Systems, Inc
6.4.8.1. Overview
6.4.8.2. Financial Performance
6.4.8.3. Service Benchmarking
6.4.8.4. Strategic Initiatives
6.4.9. Elevance Health (CarelonRx)
6.4.9.1. Overview
6.4.9.2. Financial Performance
6.4.9.3. Service Benchmarking
6.4.9.4. Strategic Initiatives
6.4.10. ExlService Holdings, Inc.
6.4.10.1. Overview
6.4.10.2. Financial Performance
6.4.10.3. Service Benchmarking
6.4.10.4. Strategic Initiatives
6.4.11. MRIoA
6.4.11.1. Overview
6.4.11.2. Financial Performance
6.4.11.3. Service Benchmarking
6.4.11.4. Strategic Initiatives
6.4.12. S&C Technologies, Inc.
6.4.12.1. Overview
6.4.12.2. Financial Performance
6.4.12.3. Service Benchmarking
6.4.12.4. Strategic Initiatives
6.5. Company Profiles: In-House Providers
6.5.1. Ultimate Health Plans
6.5.1.1. Overview
6.5.1.2. Financial Performance
6.5.1.3. Service Benchmarking
6.5.1.4. Strategic Initiatives
6.5.2. Security Health Plan of Wisconsin, Inc.
6.5.2.1. Overview
6.5.2.2. Financial Performance
6.5.2.3. Service Benchmarking
6.5.2.4. Strategic Initiatives
6.5.3. Blue Cross and Blue Shield Association
6.5.3.1. Overview
6.5.3.2. Financial Performance
6.5.3.3. Service Benchmarking
6.5.4. Providence
6.5.4.1. Overview
6.5.4.2. Financial Performance
6.5.4.3. Service Benchmarking
6.5.5. Simply Healthcare Plans, Inc
6.5.5.1. Overview
6.5.5.2. Financial Performance
6.5.5.3. Service Benchmarking
6.5.6. Health Plan of San Mateo (HPSM)
6.5.6.1. Overview
6.5.6.2. Financial Performance
6.5.6.3. Service Benchmarking
6.5.7. PerformRx
6.5.7.1. Overview
6.5.7.2. Financial Performance
6.5.7.3. Service Benchmarking
6.5.8. Aetna, Inc. (CVS Health Corp.)
6.5.8.1. Overview
6.5.8.2. Financial Performance
6.5.8.3. Service Benchmarking
6.5.8.4. Strategic Initiatives

Table 1. List of secondary sources
Table 2. List of abbreviations
Table 3. Specialty drug expenditures, 2016-2021
Table 4. U.S. drug utilization management market revenue estimates and forecast, by program type, 2018-2030 (USD Billion)
Table 5. U.S. drug utilization management market revenue estimates and forecast, by end-use, 2018-2030 (USD Billion)

Figure 1 U.S. drug utilization management market segmentation
Figure 2 U.S. drug utilization management market segmentation
Figure 3 Market research process
Figure 4 Data triangulation techniques
Figure 5 Primary research pattern
Figure 6 Market research approaches
Figure 7 Value chain-based sizing & forecasting
Figure 8 Market formulation & validation
Figure 9 Market snapshot
Figure 10 Segment snapshot
Figure 11 Competitive landscape
Figure 12 U.S. drug utilization management market: Ancillary/related market outlook
Figure 13 U.S. drug utilization management market dynamics
Figure 14 Market driver relevance analysis (Current & future impact)
Figure 15 Market restraint relevance analysis (Current & future impact)
Figure 16 U.S. drug utilization management market: Porter’s five forces analysis
Figure 17 U.S. drug utilization management market: PESTLE analysis
Figure 18 U.S. drug utilization management market: Program type segment dashboard
Figure 19 U.S. drug utilization management market: Program type market share analysis, 2023 & 2030
Figure 20 In-house market, 2018-2030 (USD Billion)
Figure 21 Outsourced market, 2018-2030 (USD Billion
Figure 22 U.S. drug utilization management market: End-use segment dashboard
Figure 23 U.S. drug utilization management market: End-use market share analysis, 2023 & 2030
Figure 24 Health plan provider/Payors market, 2018-2030 (USD Billion)
Figure 25 Pharmacies market, 2018-2030 (USD Billion)
Figure 26 PBMs market, 2018-2030 (USD Billion)
Figure 27 Company categorization: Third-party providers
Figure 28 Company market position analysis: Third-party providers
Figure 29 Strategic framework: Third-party providers
Figure 30 Company categorization: In-house providers
Figure 31 Company market position analysis: In-house providers